Study summary
An antibody-drug conjugate plus immunotherapy beat chemo plus immunotherapy as first treatment
11.2months without progression, vs 7.8 with chemo plus pembrolizumab
What was tested
Sacituzumab govitecan plus pembrolizumab against chemotherapy plus pembrolizumab, as first treatment for advanced PD-L1-positive TNBC.
What they found
- Median progression-free survival was 11.2 vs 7.8 months.
- Severe side effects were similar (71% vs 70%), but fewer people stopped treatment (12% vs 31%).
- Survival data were not yet mature.
What it means
Likely to become a first choice for advanced PD-L1-positive TNBC.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.